Author:
Kim S.J.,Kim J.S.,Kim S.C.,Kim Y.K.,Kim Y.K.,Kang J.Y.,Yoon H.K.,Song J.S.,Lee S.H.,Moon H.S.,Kim J.W.,Kim K.H.,Kim C.H.,Shim B.Y.,Kim H.K.
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference18 articles.
1. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition);Simon;Chest,2007
2. CKD-602. Chong Kun Dang;Crul;Curr Opin Invest Drugs,2003
3. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor;Lee;Arch Pharm Res,1998
4. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative;Lee;Ann N Y Acad Sci,2000
5. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献